Compare OPRX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | TLSA |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 200.8M |
| IPO Year | N/A | 2000 |
| Metric | OPRX | TLSA |
|---|---|---|
| Price | $13.48 | $1.55 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.83 | N/A |
| AVG Volume (30 Days) | 248.0K | ★ 456.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $109,506,000.00 | N/A |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $7,406.92 | ★ N/A |
| Revenue Growth | ★ 24.18 | N/A |
| 52 Week Low | $3.99 | $0.63 |
| 52 Week High | $22.25 | $2.60 |
| Indicator | OPRX | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 41.48 |
| Support Level | $12.66 | $1.39 |
| Resistance Level | $13.71 | $1.60 |
| Average True Range (ATR) | 0.68 | 0.18 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 35.81 | 41.67 |
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.